• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . C > U mutations generate immunogenic peptides in SARS-CoV-2

tetano

Editor, Senior Moderator
Nat Commun


. 2025 Nov 19;16(1):10156.
doi: 10.1038/s41467-025-65251-8. C > U mutations generate immunogenic peptides in SARS-CoV-2

Gergő Mihály Balogh[SUP] 1 2 3 [/SUP], Balázs Koncz[SUP] 4 5 [/SUP], Leó Asztalos[SUP] 6 [/SUP], Eszter Ari[SUP] 4 7 8 9 [/SUP], Nikolett Gémes[SUP] 10 [/SUP], Gábor J Szebeni[SUP] 10 11 [/SUP], Benjamin Tamás Papp[SUP] 4 5 6 [/SUP], Franciska Tóth[SUP] 4 5 12 [/SUP], Balázs Papp[SUP] 4 7 9 13 [/SUP], Csaba Pál[SUP] 14 [/SUP], Máté Manczinger[SUP] 15 16 17 [/SUP]



Affiliations
Abstract

The rapid spread of SARS-CoV-2 worldwide has given rise to numerous variants. While the impact of viral mutations on antibody escape has been extensively studied, an unresolved issue concerns how emerging mutations shape HLA-restricted T-cell immune responses. Here, we analyse SARS-CoV-2 genomic variants, showing that 27% of the mutations are C > U transitions, a phenomenon common in human RNA viruses and primarily attributed to APOBEC3 enzyme-driven mutagenesis. We find that this mutation bias generally enhances viral peptide binding to human leukocyte antigen class I (HLA-I) molecules, producing immunogenic epitopes that trigger cytotoxic adaptive immune responses in most individuals across diverse populations. We also identify several HLA-I variants that are especially well-suited for presenting viral epitopes generated by these mutations. Intriguingly, individuals carrying these specific alleles are predominantly located in South and East Asia. Finally, we show that carrying HLA-I molecules that are less likely to bind C > U-induced viral peptides increases risk for severe COVID-19 disease. Our work suggests a link between C > U hypermutation and HLA-I-based presentation of viral epitopes, which may reflect the evolutionary outcome of ancient RNA virus pandemics. More broadly, our findings imply that SARS-CoV-2 diversification leads to ongoing gains of T-cell epitopes despite natural selection favouring immune escape.


 
Back
Top